Achillion Pharmaceuticals (ACHN) Cut to Strong Sell at BidaskClub

Achillion Pharmaceuticals (NASDAQ:ACHN) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Saturday.

Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. Leerink Swann restated a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Finally, Chardan Capital restated a “neutral” rating on shares of Achillion Pharmaceuticals in a research report on Sunday, September 17th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $5.13.

Achillion Pharmaceuticals (NASDAQ ACHN) opened at $2.99 on Friday. The company has a market capitalization of $410.82, a P/E ratio of -6.10 and a beta of 1.52. Achillion Pharmaceuticals has a 52-week low of $2.69 and a 52-week high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period in the prior year, the company posted ($0.15) EPS. equities analysts forecast that Achillion Pharmaceuticals will post -0.63 earnings per share for the current year.

In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of Achillion Pharmaceuticals stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.24% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sarissa Capital Management LP acquired a new stake in shares of Achillion Pharmaceuticals in the 3rd quarter valued at $9,594,000. RTW Investments LP increased its stake in shares of Achillion Pharmaceuticals by 392.9% in the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock valued at $35,201,000 after buying an additional 6,249,312 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Achillion Pharmaceuticals by 75.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after buying an additional 1,407,108 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Achillion Pharmaceuticals by 14.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 525,612 shares of the biopharmaceutical company’s stock valued at $2,360,000 after buying an additional 68,271 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Achillion Pharmaceuticals in the 3rd quarter valued at $1,347,000. 76.92% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals (ACHN) Cut to Strong Sell at BidaskClub” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.themarketsdaily.com/2018/01/13/achillion-pharmaceuticals-achn-cut-to-strong-sell-at-bidaskclub.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply